Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33849) 33849
Book Review (5617) 5617
Publication (3107) 3107
Newsletter (381) 381
Book Chapter (192) 192
Newspaper Article (88) 88
Conference Proceeding (75) 75
Magazine Article (46) 46
Book / eBook (29) 29
Dissertation (17) 17
Data Set (4) 4
Reference (4) 4
Web Resource (3) 3
Government Document (2) 2
Transcript (2) 2
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (31097) 31097
humans (21387) 21387
animals (16873) 16873
male (8120) 8120
female (7168) 7168
mice (6889) 6889
pharmacology & pharmacy (4934) 4934
p-glycoprotein (4838) 4838
biochemistry & molecular biology (4731) 4731
glycoproteins (4678) 4678
rats (4245) 4245
expression (3634) 3634
abridged index medicus (3478) 3478
membrane glycoproteins - metabolism (3385) 3385
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (3212) 3212
cell biology (3088) 3088
cells, cultured (3013) 3013
middle aged (2879) 2879
immunology (2814) 2814
proteins (2684) 2684
research (2589) 2589
adult (2542) 2542
cell line (2466) 2466
analysis (2448) 2448
oncology (2405) 2405
neurosciences (2320) 2320
hematology (2276) 2276
dose-response relationship, drug (2165) 2165
aged (2154) 2154
signal transduction (2146) 2146
membrane glycoproteins - genetics (2081) 2081
molecular sequence data (2016) 2016
glycoproteins - metabolism (1995) 1995
apoptosis (1958) 1958
activation (1948) 1948
cancer (1940) 1940
cells (1909) 1909
cardiac & cardiovascular systems (1905) 1905
in-vitro (1856) 1856
cell line, tumor (1799) 1799
amino acid sequence (1791) 1791
mice, inbred c57bl (1708) 1708
platelet aggregation inhibitors - therapeutic use (1708) 1708
physiological aspects (1677) 1677
time factors (1674) 1674
article (1669) 1669
gene expression (1644) 1644
membrane glycoproteins - antagonists & inhibitors (1583) 1583
inhibition (1572) 1572
enzyme inhibitors - pharmacology (1540) 1540
health aspects (1519) 1519
peripheral vascular disease (1511) 1511
protein binding (1507) 1507
rats, sprague-dawley (1504) 1504
glycoprotein (1495) 1495
kinetics (1482) 1482
in-vivo (1474) 1474
receptor (1462) 1462
binding (1394) 1394
treatment outcome (1389) 1389
ligands (1345) 1345
tumor cells, cultured (1335) 1335
atp-binding cassette, sub-family b, member 1 - antagonists & inhibitors (1324) 1324
multidisciplinary sciences (1322) 1322
mice, knockout (1309) 1309
multidrug-resistance (1300) 1300
chemistry, medicinal (1259) 1259
phosphorylation (1249) 1249
inflammation (1246) 1246
atp-binding cassette, sub-family b, member 1 - metabolism (1245) 1245
research article (1236) 1236
carrier proteins - metabolism (1185) 1185
platelet aggregation inhibitors - pharmacology (1180) 1180
in vitro techniques (1174) 1174
glycoproteins - genetics (1171) 1171
disease models, animal (1155) 1155
platelet aggregation - drug effects (1142) 1142
protein (1132) 1132
medicine (1108) 1108
rna, messenger - metabolism (1097) 1097
endocrinology & metabolism (1093) 1093
multidrug resistance (1081) 1081
flow cytometry (1080) 1080
membrane glycoproteins - physiology (1079) 1079
drug resistance (1078) 1078
apoptosis - drug effects (1073) 1073
pharmacokinetics (1073) 1073
binding sites (1071) 1071
structure-activity relationship (1071) 1071
care and treatment (1042) 1042
transfection (1030) 1030
medicine, research & experimental (1012) 1012
virology (1012) 1012
rodents (995) 995
gene-expression (993) 993
membrane glycoproteins (989) 989
physiology (972) 972
antineoplastic agents - pharmacology (970) 970
risk factors (955) 955
drug interactions (949) 949
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (22) 22
Online Resources - Online (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33919) 33919
German (146) 146
French (113) 113
Japanese (79) 79
Chinese (56) 56
Russian (56) 56
Spanish (38) 38
Italian (28) 28
Polish (21) 21
Portuguese (10) 10
Danish (9) 9
Hungarian (9) 9
Dutch (5) 5
Serbian (3) 3
Czech (2) 2
Finnish (2) 2
Hebrew (2) 2
Turkish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Korean (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Signal Transducer and Activator of Transcription 3 Is the Dominant Mediator of the Anti-Inflammatory Effects of IL-10 in Human Macrophages
by Williams, Lynn and Bradley, Laura and Smith, Alexandra and Foxwell, Brian
The Journal of Immunology, ISSN 0022-1767, 01/2004, Volume 172, Issue 1, pp. 567 - 576
The signaling mechanism by which the anti-inflammatory cytokine IL-10 mediates suppression of proinflammatory cytokine synthesis remains largely unknown.... 
RHEUMATOID-ARTHRITIS | TUMOR-NECROSIS-FACTOR | DNA-BINDING | HUMAN NEUTROPHILS | TYROSINE PHOSPHORYLATION | INTERLEUKIN-10 RECEPTOR | GENE-EXPRESSION | KAPPA-B-ALPHA | IMMUNOLOGY | HUMAN MONOCYTES | MONONUCLEAR PHAGOCYTES | Protein Binding - genetics | Protein Biosynthesis | Interleukin-6 - antagonists & inhibitors | Humans | Tumor Necrosis Factor-alpha - genetics | Immunoglobulins - genetics | Lipopolysaccharides - antagonists & inhibitors | RNA, Messenger - metabolism | Suppressor of Cytokine Signaling Proteins | Repressor Proteins - antagonists & inhibitors | Antigens, CD - metabolism | Trans-Activators - physiology | Protein Tyrosine Phosphatases - antagonists & inhibitors | RNA, Messenger - biosynthesis | Protein Tyrosine Phosphatases - genetics | Inflammation Mediators - physiology | Glycoproteins - genetics | DNA-Binding Proteins - physiology | Protein Tyrosine Phosphatases - biosynthesis | DNA-Binding Proteins - antagonists & inhibitors | Signal Transduction - genetics | DNA - metabolism | Down-Regulation - genetics | Macrophages - metabolism | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | Repressor Proteins - biosynthesis | Up-Regulation - immunology | Interleukin-10 - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Adenoviruses, Human - genetics | Interleukin-10 - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Phosphorylation | Tissue Inhibitor of Metalloproteinase-1 - biosynthesis | Antigens, CD - biosynthesis | Receptors, Cell Surface | Receptors, IgG - biosynthesis | Receptors, IgG - antagonists & inhibitors | Interleukin-10 - physiology | Signal Transduction - immunology | Tissue Inhibitor of Metalloproteinase-1 - metabolism | Signaling Lymphocytic Activation Molecule Family Member 1 | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | RNA, Messenger - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | Trans-Activators - genetics | Inflammation Mediators - antagonists & inhibitors | Trans-Activators - biosynthesis | Immunoglobulins - biosynthesis | Macrophages - immunology | Inflammation Mediators - immunology | Receptors, Tumor Necrosis Factor - metabolism | Immune Sera - pharmacology | Proteins - physiology | Cells, Cultured | Glycoproteins - antagonists & inhibitors | Histocompatibility Antigens Class II - biosynthesis | Tissue Inhibitor of Metalloproteinase-1 - antagonists & inhibitors | Transcription Factors - antagonists & inhibitors | Transcription Factors - biosynthesis | Up-Regulation - genetics | DNA-Binding Proteins - genetics | DNA - antagonists & inhibitors | Glycoproteins - biosynthesis | Suppressor of Cytokine Signaling 3 Protein | Down-Regulation - immunology | Interleukin-6 - biosynthesis | Receptors, Tumor Necrosis Factor - biosynthesis | STAT3 Transcription Factor | Trans-Activators - antagonists & inhibitors | Genetic Vectors | DNA-Binding Proteins - biosynthesis | Tumor Necrosis Factor-alpha - antagonists & inhibitors | SOCS-3 protein | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Glycoprotein IIb/IIIa antagonists
: a systematic review of randomized clinical trials in patients undergoing percutaneous coronary intervention
by Ho, Chuong and Canadian Coordinating Office for Health Technology Assessment
2005, Technology report, ISBN 1894978552, Volume issue 49, vi, 72
Chemotherapy | Inhibitors | drug therapy | Coronary Disease | Randomized Controlled Trials | Review Literature | Treatment Outcome | Platelet glycoprotein GPIIb-IIIa complex | Coronary heart disease | Therapeutic use | surgery
Book
Details down arrow
3. Full Text Small-Molecule RORγt Antagonists Inhibit T Helper 17 Cell Transcriptional Network by Divergent Mechanisms
by Xiao, Sheng and Yosef, Nir and Yang, Jianfei and Wang, Jinsong and Wang, Yonghui and Zhou, Ling and Zhu, Chen and Wu, Chuan and Baloglu, Erkan and Schmidt, Darby and Ramesh, Radha and Lobera, Mercedes and Sundrud, Mark S and Tsai, Pei-Yun and Xiang, Zhijun and Xu, Yan and Lin, Xichen and Kretschmer, Karsten and Rahl, Peter B and Young, Richard A and Zhong, Zhong and Hafler, David A and Regev, Aviv and Ghosh, Shomir and Marson, Alexander and Kuchroo, Vijay K
Immunity, ISSN 1074-7613, 04/2014, Volume 40, Issue 4, pp. 477 - 489
We identified three retinoid-related orphan receptor gamma t (RORγt)-specific inhibitors that suppress T helper 17 (Th17) cell responses, including... 
PATHWAYS | TARGET GENES | FOXP3 OCCUPANCY | T(H)17 | REGULATORY NETWORK | RECEPTOR | DIFFERENTIATION | IMMUNOLOGY | PSORIASIS | ANTI-INTERLEUKIN-17 MONOCLONAL-ANTIBODY | TH17 CELLS | Myelin-Oligodendrocyte Glycoprotein - immunology | T-Lymphocyte Subsets - immunology | Transcription, Genetic - drug effects | Nuclear Receptor Subfamily 1, Group F, Member 3 - antagonists & inhibitors | Humans | Transcriptional Activation - drug effects | Encephalomyelitis, Autoimmune, Experimental - immunology | Structure-Activity Relationship | Gene Regulatory Networks - drug effects | Cell Lineage - drug effects | Systems Biology | Benzhydryl Compounds - chemistry | Heterocyclic Compounds, 4 or More Rings - pharmacology | Th17 Cells - drug effects | T-Lymphocyte Subsets - drug effects | Peptide Fragments - immunology | Protein Binding - drug effects | Benzeneacetamides - chemistry | Benzeneacetamides - pharmacology | Nuclear Receptor Subfamily 1, Group F, Member 3 - genetics | Cytokines - metabolism | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Heterocyclic Compounds, 4 or More Rings - chemistry | Digoxin - chemistry | Digoxin - pharmacology | Mice, Knockout | Animals | Androstenols - chemistry | Cell Differentiation - drug effects | Cell Line, Tumor | Multiple Sclerosis - immunology | Th17 Cells - immunology | Benzhydryl Compounds - pharmacology | Mice | Multiple Sclerosis - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion
by Li, Ning and Li, Bin and Brun, Thierry and Deffert-Delbouille, Christine and Mahiout, Zahia and Daali, Youssef and Ma, Xiao-Juan and Krause, Karl-Heinz and Maechler, Pierre
Diabetes, ISSN 0012-1797, 11/2012, Volume 61, Issue 11, pp. 2842 - 2850
In insulin-secreting cells, expression of NADPH oxidase (NOX), a potent source of ROS, has been reported, along with controversial findings regarding its... 
SIGNAL-TRANSDUCTION | NAD(P)H OXIDASE | RESPIRATORY BURST | OXIDATIVE STRESS | PROTEIN | ISLETS | SUPEROXIDE-PRODUCTION | ENDOTHELIAL-CELLS | ENDOCRINOLOGY & METABOLISM | PANCREATIC BETA-CELLS | DEPENDENT PATHWAY | Islets of Langerhans - drug effects | Reactive Oxygen Species - metabolism | Membrane Glycoproteins - metabolism | Humans | NADPH Oxidases - metabolism | Secretory Vesicles - metabolism | Insulin-Secreting Cells - metabolism | Membrane Glycoproteins - antagonists & inhibitors | Islets of Langerhans - metabolism | Isoenzymes - metabolism | Islets of Langerhans - cytology | NADPH Oxidases - genetics | Insulin-Secreting Cells - cytology | Cyclic AMP-Dependent Protein Kinases - antagonists & inhibitors | Cyclic AMP - metabolism | Insulin Secretion | Cyclic AMP-Dependent Protein Kinases - metabolism | Second Messenger Systems - drug effects | Glucagon-Like Peptide 1 - metabolism | Isoenzymes - genetics | Tissue Culture Techniques | Mice, Inbred C57BL | NADPH Oxidases - antagonists & inhibitors | Cells, Cultured | Gene Silencing | NADPH Oxidase 2 | Membrane Glycoproteins - genetics | Mice, Knockout | Cyclic AMP - antagonists & inhibitors | Insulin - metabolism | Animals | Insulin-Secreting Cells - drug effects | Secretory Vesicles - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Cyclic AMP - agonists | Isoenzymes - antagonists & inhibitors | Oxidases | Physiological aspects | Pancreatic beta cells | Research | Analysis | NADP (Coenzyme) | Index Medicus | Abridged Index Medicus | Islet Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
by Drilon, Alexander and Siena, Salvatore and Ou, Sai-Hong Ignatius and Patel, Manish and Ahn, Myung Ju and Lee, Jeeyun and Bauer, Todd M and Farago, Anna F and Wheler, Jennifer J and Liu, Stephen V and Doebele, Robert and Giannetta, Laura and Cerea, Giulio and Marrapese, Giovanna and Schirru, Michele and Amatu, Alessio and Bencardino, Katia and Palmeri, Laura and Sartore-Bianchi, Andrea and Vanzulli, Angelo and Cresta, Sara and Damian, Silvia and Duca, Matteo and Ardini, Elena and Li, Gang and Christiansen, Jason and Kowalski, Karey and Johnson, Ann D and Patel, Rupal and Luo, David and Chow-Maneval, Edna and Hornby, Zachary and Multani, Pratik S and Shaw, Alice T and De Braud, Filippo G
Cancer Discovery, ISSN 2159-8274, 04/2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists
by Zhang, Fengwen and Wilson, Sam J and Landford, Wilmina C and Virgen, Beatriz and Gregory, Devon and Johnson, Marc C and Munch, Jan and Kirchhoff, Frank and Bieniasz, Paul D and Hatziioannou, Theodora
Cell Host & Microbe, ISSN 1931-3128, 2009, Volume 6, Issue 1, pp. 54 - 67
The tetherin/BST2/CD317 protein blocks the release of HIV-1 and other enveloped viruses by inducing tethering of nascent particles to infected cell surfaces.... 
TYPE-2 ENVELOPE PROTEIN | INHIBITS HIV-1 | PARTICLE RELEASE | RHESUS-MONKEYS | CELL-SURFACE EXPRESSION | INFECTIVITY | MICROBIOLOGY | RESTRICTION | CD4 | VIROLOGY | VPU PROTEIN | GLYCOPROTEIN | PARASITOLOGY | Amino Acid Sequence | Antigens, CD - immunology | Cell Line | Humans | GPI-Linked Proteins | Molecular Sequence Data | Simian Immunodeficiency Virus - growth & development | Haplorhini | Animals | Membrane Glycoproteins - antagonists & inhibitors | Membrane Glycoproteins - immunology | Gene Products, nef - immunology | Simian Immunodeficiency Virus - immunology | Virus diseases | Antiviral agents | Monkeys | Universities and colleges | Viral proteins | HIV (Viruses) | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
by Tricoci, Pierluigi and Huang, Zhen and Held, Claes and Moliterno, David J and Armstrong, Paul W and Van de Werf, Frans and White, Harvey D and Aylward, Philip E and Wallentin, Lars and Chen, Edmond and Lokhnygina, Yuliya and Pei, Jinglan and Leonardi, Sergio and Rorick, Tyrus L and Kilian, Ann M and Jennings, Lisa H.K and Ambrosio, Giuseppe and Bode, Christoph and Cequier, Angel and Cornel, Jan H and Diaz, Rafael and Erkan, Aycan and Huber, Kurt and Hudson, Michael P and Jiang, Lixin and Jukema, J. Wouter and Lewis, Basil S and Lincoff, A. Michael and Montalescot, Gilles and Nicolau, José Carlos and Ogawa, Hisao and Pfisterer, Matthias and Prieto, Juan Carlos and Ruzyllo, Witold and Sinnaeve, Peter R and Storey, Robert F and Valgimigli, Marco and Whellan, David J and Widimsky, Petr and Strony, John and Harrington, Robert A and Mahaffey, Kenneth W and TRACER Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 20 - 33
In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the... 
MEDICINE, GENERAL & INTERNAL | DESIGN | GLYCOPROTEIN IIB/IIIA INHIBITORS | CLOPIDOGREL | RATIONALE | DOUBLE-BLIND | PHASE-II | PLACEBO-CONTROLLED TRIAL | ST-SEGMENT ELEVATION | ASPIRIN | ANTIPLATELET THERAPY | Follow-Up Studies | Angioplasty | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Combined Modality Therapy | Lactones - adverse effects | Lactones - therapeutic use | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Coronary Artery Bypass | Acute Coronary Syndrome - therapy | Aged | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Cardiovascular disease | Hemorrhage | Bleeding | Investigations | Manuscripts | Ischemia | Blood platelets | Acute coronary syndromes | Research centers | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Bypass cardiopulmonar | Medicaments | Bypass cardiopulmonary | Plaquetes sanguínies | Cardiovascular diseases | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
by Anthony E. Boitano and Jian Wang and Russell Romeo and Laure C. Bouchez and Albert E. Parker and Sue E. Sutton and John R. Walker and Colin A. Flaveny and Gary H. Perdew and Michael S. Denison and Peter G. Schultz and Michael P. Cooke
Science, ISSN 0036-8075, 9/2010, Volume 329, Issue 5997, pp. 1345 - 1348
Although practiced clinically for more than 40 years, the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells... 
Hep G2 cells | Cytokines | REPORTS | Stem cells | Multipotent stem cells | Bone marrow | Cultured cells | Transplantation | Aryl hydrocarbon receptors | Hematopoietic stem cells | Blood | EX-VIVO EXPANSION | ENGRAFTMENT | MULTIDISCIPLINARY SCIENCES | BONE-MARROW | BIOLOGY | MICE | UMBILICAL-CORD BLOOD | BINDING | TRANSPLANTATION | Antigens, CD34 - analysis | Cell Proliferation | Receptors, Aryl Hydrocarbon - antagonists & inhibitors | Species Specificity | Cell Count | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Antigens, CD - analysis | Multipotent Stem Cells - drug effects | Hematopoiesis | Polychlorinated Dibenzodioxins - pharmacology | Hematopoietic Stem Cells - physiology | Receptors, Aryl Hydrocarbon - metabolism | Multipotent Stem Cells - physiology | Hematopoietic Stem Cells - drug effects | Signal Transduction | Purines - metabolism | Purines - pharmacology | Cells, Cultured | Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cells - metabolism | Mice, SCID | AC133 Antigen | Aryl Hydrocarbon Hydroxylases - metabolism | Cell Lineage | Animals | Multipotent Stem Cells - cytology | Small Molecule Libraries | Hematopoietic Stem Cells - cytology | Cytochrome P-450 CYP1B1 | Mice, Inbred NOD | Mice | Glycoproteins - analysis | Cytokines - pharmacology | Peptides - analysis | Physiological aspects | Arylation | Human | Receptors | Aromatic compounds | Modulation | Hydrocarbons | Derivatives | Culture | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [18F]-PET Imaging in a Primate Brain
by Deau, Emmanuel and Robin, Elodie and Voinea, Raluca and Percina, Nathalie and Satała, Grzegorz and Finaru, Adriana-Luminita and Chartier, Agnès and Tamagnan, Gilles and Alagille, David and Bojarski, Andrzej J and Morisset-Lopez, Séverine and Suzenet, Franck and Guillaumet, Gérald
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2015, Volume 58, Issue 20, pp. 8066 - 8096
We report the synthesis of 46 tertiary amine-bearing N-alkylated benzo[d]imidazol-2(3H)-ones, imidazo-[4,5-b]pyridin-2(3H)-ones,... 
MEDICINAL CHEMISTRY | CHEMISTRY, MEDICINAL | SELECTIVE 5-HT2A | PHARMACOLOGICAL CHARACTERIZATION | ANTIPSYCHOTIC-DRUGS | SEROTONIN RECEPTORS | PSYCHIATRIC-DISORDERS | CENTRAL-NERVOUS-SYSTEM | IN-VIVO EVALUATION | HIPPOCAMPAL-NEURONS | P-GLYCOPROTEIN | Brain - diagnostic imaging | Receptors, Serotonin - drug effects | Serotonin Antagonists - chemical synthesis | Macaca mulatta | Positron-Emission Tomography | Structure-Activity Relationship | Serotonin Antagonists - pharmacology | Radiopharmaceuticals - chemical synthesis | Animals | Image Processing, Computer-Assisted | Drug Design | Isotope Labeling | Ligands | Receptor, Serotonin, 5-HT2A - drug effects | Radiopharmaceuticals - pharmacology | Blood-Brain Barrier | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Mechanisms of synergism between antagonists of growth hormone‐releasing hormone and antagonists of luteinizing hormone‐releasing hormone in shrinking experimental benign prostatic hyperplasia
by Rick, Ferenc G and Schally, Andrew V and Block, Norman L and Abi‐Chaker, Andrew and Krishan, Awtar and Szalontay, Luca
The Prostate, ISSN 0270-4137, 06/2013, Volume 73, Issue 8, pp. 873 - 883
BACKGROUND Benign prostatic hyperplasia (BPH) affects aging men. Combined therapy with antagonists of growth hormone-releasing hormone (GHRH) and of... 
LHRH antagonist | GHRH antagonist | prostatic inflammation | prostate | medical therapy | GnRH | benign prostatic hyperplasia | CELLS | INTRAEPITHELIAL NEOPLASIA | PATHOGENESIS | LHRH | INHIBITION | GHRH | ENDOCRINOLOGY & METABOLISM | UROLOGY & NEPHROLOGY | PPAR-GAMMA | CANCER PROGRESSION | RECEPTORS | EXPRESSION | Cell Line | Cell Survival - drug effects | Prostatic Hyperplasia - pathology | Rats, Wistar | Humans | Gonadotropin-Releasing Hormone - pharmacology | Organ Size | Rats | Cell Cycle Checkpoints - physiology | Male | Gene Expression Profiling | Gonadotropin-Releasing Hormone - antagonists & inhibitors | Down-Regulation - drug effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Drug Synergism | Animals | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | Sermorelin - pharmacology | Sermorelin - analogs & derivatives | Growth Hormone-Releasing Hormone - antagonists & inhibitors | Prostatic Hyperplasia - drug therapy | Testosterone | Somatotropin | Somatotropin releasing hormone | Analysis | Luteinizing hormone | Glycoproteins | Hormones | Prostate | Hypertrophy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights